Pacira BioSciences, Inc. — Director's Dealing 2014

May 10, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pacira Pharmaceuticals, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2014-05-08

Reporting Person: Scibetta James S (SVP, Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-05-08	Common Stock	M	15000	$1.61	Acquired	20000	Direct
2014-05-08	Common Stock	S	3300	$74.27	Disposed	16700	Direct
2014-05-08	Common Stock	S	11400	$75.25	Disposed	5300	Direct
2014-05-08	Common Stock	S	300	$75.80	Disposed	5000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-05-08	Employee Stock Option (right to buy)	$1.61	M	15000	Disposed	2020-09-02	Common Stock (15000)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.605 to $74.54, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.63 to $75.53, inclusive.

F4: The option vested as to 25% of the options on September 2, 2011 and vests as to the remaining options in successive equal monthly installments for the subsequent 36 months. The options became exercisable, to the extent vested, from and after the Issuer's initial public offering.